No Picture
Trading Ideas

Exclusive: Pershing Square's Ackman eyes $1 billion-plus 'blank-check' company – sources

Ackman, whose New York-based hedge fund has more than $10 billion in assets under management, is working with investment banks Jefferies, UBS Group AG and Citigroup Inc on the IPO, referred to on Wall Street as a special purpose acquisition company (SPAC), the sources said. The sources requested anonymity because the IPO is still confidential. …read more […]

No Picture
Trading Ideas

Exclusive: Pershing Square's Ackman eyes $1 billion-plus 'blank-check' company – sources

Ackman, whose New York-based hedge fund has more than $10 billion in assets under management, is working with investment banks Jefferies, UBS Group AG and Citigroup Inc on the IPO, referred to on Wall Street as a special purpose acquisition company (SPAC), the sources said. The sources requested anonymity because the IPO is still confidential. …read more […]

No Picture
Trading Ideas

Beyond Meat Boosts Europe Presence As Global Expansion Continues

Plant-based meat pioneer Beyond Meat (BYND) has announced the company’s first co-manufacturing capabilities in Europe with the opening of the Zandbergen co-manufacturing facility in Zoeterwoude, the Netherlands.The new facility, which is owned and operated by Zandbergen, will produce the Beyond Burger and Beyond Sausage, and BYND hopes it will enable more efficient distribution of Beyond Meat’s products across EMEA.This week, Beyond Meat also snapped up its first manufacturing facility in Europe in Enschede, the Netherlands. This Beyond Meat owned facility will be the first outside of Missouri, USA to handle Beyond Meat’s texturizing of plant proteins, the first step in …read more […]

No Picture
Trading Ideas

Moderna to start final testing stage of coronavirus vaccine in July

Moderna Inc on Thursday confirmed it plans to start a trial of 30,000 volunteers of its much-anticipated coronavirus vaccine in July as the company enters the final stage of testing. The Cambridge, Massachusetts-based biotech said the primary goal of the study would be to prevent symptomatic COVID-19, the disease caused by the novel coronavirus. The key secondary goal would be prevention of severe disease, as defined by keeping people out of the hospital. …read more […]